Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol. 1941;168:9–12.
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer, version 2. 2016. 2016. [cited 2016 Feb 21]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Onc. 2011;29(27):3651–3658.
   PubMed Web of Science ®Google Scholar
• Black BE, Paschal BM. Intranuclear organization and function of the androgen receptor. Tem. 2004;15(9):411–417.
   PubMed Web of Science ®Google Scholar
• Wadosky KM, Koochekpour S. Therapeutic rationales, progresses, failures, and future directions for advanced prostate cancer. Int J Biol Sci. 2016;12(4):409–426.
   PubMed Web of Science ®Google Scholar
• Schally AV, Coy DH. Stimulatory and inhibitory analogs of luteinizing hormone releasing hormone (LHRH). Adv Exp Med Biol. 1977;87:99–121.
   PubMedGoogle Scholar
• Eisenberger MA, O’Dwyer PJ, Friedman MA. Gonadotropin Hormone-releasing hromone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Onc. 1986;4(3):414–424.
   PubMed Web of Science ®Google Scholar
• Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. The Oncologist. 2000;5(2):162–168.
   PubMedGoogle Scholar
• Bhasin S, Berman N, Swerdloff RS. Follicle-stimulating hromone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatments. J Androl. 1994;15:386–391.
   PubMed Web of Science ®Google Scholar
• Garnick MD, Campion M. Abarelix depot, a GnRH antagonist, v LHRH super-agonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Deport Study group. Mol Urol. 2000;4:275–277.
   PubMedGoogle Scholar
• Bubley GJ. Is the flare phenomenon clincally significant?. Urology. 2001;58:5–9.
   PubMed Web of Science ®Google Scholar
• van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?. Urology. 2008;71:1001–1006.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Eng J Med. 1989;321:419–424.
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Belanger A, et al. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol. 1987;138(4):804–806.
   PubMed Web of Science ®Google Scholar
• Shulze H, Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol. 1990;144:934–941.
   PubMed Web of Science ®Google Scholar
• Kuhn J, Billebaud T, Navratil H, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Eng J Med. 1989;321(7):413–418.
   PubMed Web of Science ®Google Scholar
• Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol. 2001;3(suppl 3):SS10-4.
   Google Scholar
• Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix deport versus luteinizing hormone releasing hormone agonists leuprolide or goserlin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol. 2001;165(5):1585–1589.
   PubMed Web of Science ®Google Scholar
• Lin BJT, Chen K, Chen M, et al. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology. 1994;43(6):834–837.
   PubMed Web of Science ®Google Scholar
• Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132:566–577.
   PubMed Web of Science ®Google Scholar
• Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002;167(4):1670–1674.
   PubMed Web of Science ®Google Scholar
• Koch M, Steidle C, Brosman S, et al. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology. 2003;62(5):877–882.
   PubMed Web of Science ®Google Scholar
• Gittelman M, Pommerville PJ, Persson BE, et al. A 1-year, open label, randomized phase II dose finding study of Degarelix for the treeatment of prostate cancer in North America. J Urol. 2008;180:1986–1992.
   PubMed Web of Science ®Google Scholar
• Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label parallel-group phase III study in patients with prostate cancer. Br J Urol Int. 2008;102:1531–1538.
   Google Scholar
• Jiang G, Stalewski J, Galyean R, et al. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanies at positions 5 and 6. J Med Chem. 2001;44(3):4553–4567.
   Web of Science ®Google Scholar
• Klotz L. Pharmacokinetic and pharmacodynami profile for degarelix for prostate cancer. Expert Opin Drug Metab Toxicol. 2015;11(11):1795–1802.
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, van der Meulen E, Persson BE. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol. 2011;3(3):127–140.
   PubMedGoogle Scholar
• Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Uro. 2004;46:279–284.
   PubMed Web of Science ®Google Scholar
• Tornoe CW, Agerso H, Nielsen HA, et al. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist Degarelix. Pharm Res. 2004;21(4):574–584.
   PubMed Web of Science ®Google Scholar
• Firmagon (degarelix for inection) US prescribing information. [cited 2017 Feb 21]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022201s003lbl.pdf
   Google Scholar
• Sonesson A, Koechling W, Stalewski J, et al. Metabolite Profiles of Degareix, a new gonadtropin-releasing hormone receptor antagonist, in rat, dog and monkey. Drug Metabolism and Dispos. 2011;39(10):1895–1903.
   PubMed Web of Science ®Google Scholar
• Sonesson A, Rasmussen BB. In vitro and in vivo human metabolism of degarelix, a gonadotropin-releasing hromone receptor blocker. ‎Drug Metab Dispos. 2013;41(7):1339–1346.
   PubMed Web of Science ®Google Scholar
• Shaw GL, Whitaker H, Corcoran M, et al. The early effects of rapid androgen deprivation on human prostate cancer. Eur Urol. 2016;70:214–218.
   PubMed Web of Science ®Google Scholar
• Shore ND, Abrahamsson PA, Andersone J, et al. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013;16:7–15.
   PubMed Web of Science ®Google Scholar
• Zinner NR, Bidair M, Centeno A, et al. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6mg and 10.8mg: results of a randomized open-label trial. Urology. 2004;64:1177–1181.
   PubMed Web of Science ®Google Scholar
• Oduwole O, Rawson P, Rahman N, et al. FSH supplementation increases the growth of PC-3 human prostate cancer cell xenograft in gonadotropin-suppressed nude mice. 18th European Congress of Endocrinology, May 2016 Munich, Germany: European Society of Endocrinology. Endocrine Abstracts 2016;4:GP117
   Google Scholar
• Sayyid RK, Evans A, Hersey K, et al. A phase II, randomized, open-label study of neoadjuvant degarelix versus LHRH agonist in prostate cancer patients prior to radical prostatectomy. Clin Cancer Res. 2016 cited 2017 February 2. DOI:10.1158/1078-0432.CCR-16-1790
   PubMed Web of Science ®Google Scholar
• Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Onc. 2009;27:2450–2456.
   PubMed Web of Science ®Google Scholar
• Swensson USH, Senderovitz T, Karlsson MO. Population PK/PD modeling of testosterone (T), LH and dihydrotestosterone (DHT) response to single SC degarelix in male volunteers. Am Soc Clin Pharmacol Ther. 2003;73(2):87.
   PubMed Web of Science ®Google Scholar
• van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker–results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008;54:805–813.
   PubMed Web of Science ®Google Scholar
• Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010;57:836–842.
   PubMed Web of Science ®Google Scholar
• Schroder FH, Tombal B, Miller K, et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2010;106:182–187.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011;186:889–897.
   PubMed Web of Science ®Google Scholar
• Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66:1101–1108.
   PubMed Web of Science ®Google Scholar
• Anderson J, Al-Ali G, Wirth M, et al. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233). Urol Int. 2013;90:321–328.
   PubMed Web of Science ®Google Scholar
• Mason M, Maldonado Pijoan X, Steidle C, et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. Clin Oncol (R Coll Radiol). 2013;25:190–196.
   PubMed Web of Science ®Google Scholar
• Axcrona K, Aaltomaa S, Da Silva CM, et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int. 2012;110:1721–1728.
   PubMed Web of Science ®Google Scholar
• Tombal B, Tammela TLJ, Wolff JM, et al. Efficacy and safety of a 3-monthly depot of degarelix compared with goserelin in prostate cancer. Eur Urol Supp. 2012;11(5):109.
   Google Scholar
• Schulman C, Cornel E, Matveev V, et al. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (ICELAND). Eur Urol. 2016;69:720–727.
   PubMed Web of Science ®Google Scholar
• Crook JM, O’Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Eng J Med. 2012;367:895–903.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–479.
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, Albers P, Morote J, et al. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. Eur Urol. 2014;66:655–663.
   PubMed Web of Science ®Google Scholar
• Lowrance WT, Roth BJ, Kirkby E, et al. Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol. 2016;195:1444–1452.
   PubMed Web of Science ®Google Scholar
• Miller K, Simson G, Goble S, et al. Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27). Ther Adv Urol. 2015;7:105–115.
   PubMedGoogle Scholar
• Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and Goserelin. N Eng J Med. 1997;337:295–300.
   PubMed Web of Science ®Google Scholar
• Miki K, Sasaki H, Kido M, et al. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer. BMC Cancer. 2016;16:708.
   PubMed Web of Science ®Google Scholar
• Degarelix acetate before and during radiation therapy in treating patients with prostate cancer (NCT01731912). [cited 2017 Feb 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT01731912
   Google Scholar
• Sountoulides P, Rountos T. Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol. 2013;2013:1–8.
   PubMedGoogle Scholar
• Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–836.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Shore ND, Moul JW, et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology. 2014;83:1122–1128.
   PubMed Web of Science ®Google Scholar
• Koechling W, Hjortkjaer R, Tanko LB. Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. 2010;70:580–587.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. Jama. 2011;306(21):2359–2366.
   PubMed Web of Science ®Google Scholar
• Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–396.
   PubMed Web of Science ®Google Scholar
• Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565–573.
   PubMed Web of Science ®Google Scholar
• A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (PRONOUNCE). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02663908
   Google Scholar
• Hopmans SN, Duivenvoorden WC, Werstuck GH, et al. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Uro Onc. 2014;32:1126–1134.
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Eng J Med. 2005;352:1685–1695.
   PubMed Web of Science ®Google Scholar
• Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–3488.
   PubMed Web of Science ®Google Scholar
• Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med. 1998;3:199–206.
   PubMedGoogle Scholar
• Knutsson A, Hsiung S, Celik S, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice. Sci Rep. 2016;6:26220.
   PubMed Web of Science ®Google Scholar
• Radu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Eng J Med. 2010;363:1621–1630.
   PubMed Web of Science ®Google Scholar
• Chen HF, Jeung EB, Stephenson M, et al. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab. 1999;84:743–750.
   PubMed Web of Science ®Google Scholar
• Tanriverdi F, Gonzalez-Martinez D, Hu Y, et al. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol. 2005;142:103–110.
   PubMed Web of Science ®Google Scholar
• Dixit VD, Yang H, Udhayakumar V, et al. Gonadotropin-releasing hormone alters the T helper cytokine balance in the pregnant rat. Biol Reprod. 2003;68:2215–2221.
   PubMed Web of Science ®Google Scholar
• Lu L, Peters J, Roome C, et al. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int. 2012;109:1183–1192.
   PubMed Web of Science ®Google Scholar
• Lee D, Porter J, Gladwell D, et al. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom. J Med Econ. 2014;17:233–247.
   PubMedGoogle Scholar
• Hatoum HT, Crawford ED, Nielsen SK, et al. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2013;13:261–270.
   PubMed Web of Science ®Google Scholar